AI models can modify the genetic sequences of known bioweapons like ricin just enough to evade current screening protocols at DNA synthesis companies. This creates functional but 'obfuscated' threats, demonstrating a critical vulnerability in our biodefense supply chain.

Rion found that culturing stem cells in a lab to force division leads to rapid DNA damage, as cells are not designed for this artificial environment. This damage created inconsistent exosome products, making large-scale, uniform manufacturing from stem cells unfeasible and prompting a search for a more stable source.

DMSO's toxicity extends to the epigenetic level with a paradoxical effect. It can upregulate enzymes that add methyl groups (hypermethylation), silencing genes, while also promoting enzymes that remove them (hypomethylation), activating others. This disruption creates widespread genomic instability with unknown long-term consequences for cell therapy products.

Failing to conduct comprehensive screening for strain selection and media development at the project's start creates issues that become significantly more difficult and expensive to resolve later. Small, early-stage problems can derail downstream processing and scale-up efforts entirely.

Standard post-thaw viability tests are misleading for cell therapies. DMSO can cause profound, non-lethal damage by altering gene expression, inducing differentiation in stem cells, and impairing T-cell function. Cells may be 'alive' but therapeutically impotent, a risk not captured by simple viability metrics.

Unlike a drug that can be synthesized to a chemical standard, most vaccines are living biological products. This means the entire manufacturing process must be perfectly managed and cannot be altered without re-validation. This biological complexity makes production far more difficult and expensive than typical pharmaceuticals.

The danger of AI creating harmful proteins is not in the digital design but in its physical creation. A protein sequence on a computer is harmless. The critical control point is the gene synthesis process. Therefore, biosecurity efforts should focus on providing advanced screening tools to synthesis providers.

Continuous microbial manufacturing lags behind mammalian systems primarily due to the high replication rate of microbes like E. coli, which causes rapid genetic drift and loss of productivity. The solution is biological, not mechanical: decoupling cell growth from protein production to genetically stabilize the system for long-duration runs.

While 80% of DNA synthesis companies voluntarily screen orders for dangerous pathogen sequences, the system is not mandatory. This creates a glaring loophole, as a malicious actor can simply place their order with the 20% of companies that do not perform this critical safety check.